Your search for 06/2015 returned 6 results.

HCV DAAs and Severe Renal Impairment

New report provides vital information needed by clinicians to treat HCV in patients with severe renal impairment with the approved DAAs simeprevir and sofosbuvir. Available clinical information on the use of sofosbuvir in patients with severe renal impairment is minimal, and there are currently no approved direct acting antiviral (DAA) treatments in this popula...

Read More

Interventions in the HCV care continuum

New systematic review in the journal International Journal of Drug Policy discusses published evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum. Authors note that primary care settings represent key opportunities for HCV care linkage interventions, often within clinics that have prolonged engagement ...

Read More

Liver transplant failure risk: Females with HCV

Prospective Liver Match study unequivocally shows that female gender is a risk factor for graft loss after liver transplantation for hepatitis C virus (HCV)-related cirrhosis. Women lose their graft more frequently than men, secondary to more aggressive recurrent HCV infection. This study also confirms that the use of elderly donors is a strong predictor of poor ...

Read More

Coffee Decreases HCV Advanced Fibrosis Risk

New study indicates that an average daily intake of an estimated 100 mg of caffeine from coffee, tea, or soda is associated with an approximately one-third reduction in odds of advanced fibrosis, although higher intake does not seem to confer any additional benefit. Interestingly, tea intake in those who do not consume coffee may also be associated with a decrea...

Read More

Hepatitis C RAVs are Not a Barrier to Retreatment

Study published in the journal Hepatology suggests that sofosbuvir plus peginterferon and ribavirin for 12 weeks is effective and safe in patients who have not achieved SVR with prior regimens of one or more direct-acting antiviral (DAA) agents plus peginterferon and ribavirin. High rates of SVR12 are achieved regardless of the presence of resistance associated ...

Read More

Dr. E Lebovics: Post-EASL 2015 HCV Interview

During our last interview, you mentioned that extending the use of all oral, interferon-free, hepatitis C regimens to special populations including those with decompensated cirrhosis, post-transplant, and renal failure is an area of great interest. We would like to hear your thoughts on relevant clinical data presented at The International Liver Congress™ 2015, ...

Read More